Browsing by Author Kalincik, Tomas

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 8 of 8
Issue DateTitleAuthor(s)Citation
2015Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosisBarnett, Michael; Bergamaschi, R; Duquette, P; et al, Various; Girard, Marc; Grammond, P; Hupperts, Raymond; Izquierdo, Guillermo; Jokubaitis, Vilija; Kalincik, Tomas; Lugaresi, Alessandra; Oreja-Guevara, Celia; Central Clinical School: Inst. of Clinical NeurosciencesComparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis, Multiple Sclerosis Journal, vol.21, 9, 2015,pp 1159-1171
2015Comparative efficacy of switching to natalizumab in active multiple sclerosisBarnett, Michael; Belachew, Shibeshih; et al, Various; Hyde, Robert; Kalincik, Tomas; Kappos, L.; Pellegrini, Fabio; Spelman, Timothy; Tsvetkova, Larisa; Wiendl, Heinz; Zhang, Annie; Central Clinical School: Inst. of Clinical NeurosciencesComparative efficacy of switching to natalizumab in active multiple sclerosis, Annals of Clinical and Translational Neurology, vol.2, 4, 2015,pp 373-387
2015Defining reliable disability outcomes in multiple sclerosisBarnett, Michael; Cutter, Gary; Duquette, P; et al, Various; Girard, Marc; Havrdova, Eva; Horakova, Dana; Izquierdo, Guillermo; Jokubaitis, Vilija; Kalincik, Tomas; Spelman, Vilija; Trojano, Maria; Central Clinical School: Inst. of Clinical NeurosciencesDefining reliable disability outcomes in multiple sclerosis, Brain, vol.138, 11, 2015,pp 3287-3298
2014Fingolimod after natalizumab and the risk of short-term relapseBarnett, Michael; Alroughani, Raed; Duquette, P; et al, Various; Girard, Marc; Hodgkinson, S.; Izquierdo, Guillermo; Jokubaitis, Vilija; Kalincik, Tomas; Lechner-Scott, Jeanette; Li, Vivien; Lugaresi, Alessandra; Central Clinical School: Inst. of Clinical NeurosciencesFingolimod after natalizumab and the risk of short-term relapse, Neurology, vol.82, 14, 2014,pp 1204-1211
2015Predictors of disability worsening in clinically isolated syndromeBarnett, Michael; Boz, Cavit; Cabrera-Gomez, Jose; Duquette, P; et al, Various; Girard, Marc; Giuliani, G; Grammond, P; Grand'Maison, Francois; Hupperts, R; Izquierdo, Guillermo; Jokubaitis, Vilija; Kalincik, Tomas; Lugaresi, Alessandra; Oreja-Guevara, C; Spelman, Timothy; Central Clinical School: Inst. of Clinical NeurosciencesPredictors of disability worsening in clinically isolated syndrome, Annals of Clinical and Translational Neurology, vol.2, 5, 2015,pp 479-491
2013Sex as a determinant of relapse incidence and progressive course of multiple sclerosisBarnett, Michael; Vucic, Steve; Bergamaschi, R; et al, Various; Grand'Maison, Francois; Hupperts, R; Izquierdo, G; Jokubaitis, Vilija; Kalincik, Tomas; Lechner-Scott, Jeanette; Lugaresi, Alessandra; Oreja-Guevara, C; Trojano, Maria; Vivek, Vino; Central Clinical School: Inst. of Clinical Neurosciences; Western Clinical School: Medicine (Westmead)Sex as a determinant of relapse incidence and progressive course of multiple sclerosis, Brain, vol.136, 12, 2013,pp 3609-3617
2015Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosisBarnett, Michael; Alroughani, Raed; Duquette, P; et al, Various; Girard, Marc; Grammond, P; Horakova, Dana; Izquierdo, Guillermo; Jokubaitis, Vilija; Kalincik, Tomas; Lechner-Scott, Jeannette; Lugaresi, Alessandra; Pucci, Eugenio; Rozsa, Csilla; Spelman, Timothy; Trojano, Maria; Central Clinical School: Inst. of Clinical NeurosciencesSwitch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis, Annals of Neurology, vol.77, 3, 2015,pp 425-435
2017Towards personalized therapy for multiple sclerosis: Prediction of individual treatment responseBarnett, Michael; Vucic, Steve; et al, Various; Havrdova, Eva; Horakova, Dana; Izquierdo, Guillermo; Jokubaitis, Vilija; Kalincik, Tomas; Manouchehrinia, Ali; Sobisek, Lukas; Spelman, Timothy; Trojano, Maria; Central Clinical School: Inst. of Clinical Neurosciences; Westmead Clinical School: MedicineTowards personalized therapy for multiple sclerosis: Prediction of individual treatment response, Brain, vol.140, 9, 2017,pp 2426-2443